17-Hydroxyprogesterone Caproate for the Prevention of Recurrent Preterm Birth - A Systematic Review and Meta-analysis Taking into Account the PROLONG Trial.

Conclusion Based on the currently available data, 17-OHPC cannot be recommended for the prevention of recurrent preterm birth. Further randomized, placebo-controlled studies with clearly defined, comparable risk factors are required to identify the group of pregnant women which could benefit from the use of 17-OHPC to prevent preterm birth. PMID: 33487666 [PubMed]

https://www.ncbi.nlm.nih.gov/pubmed/33487666?dopt=Abstract

Source: Geburtshilfe und Frauenheilkunde - January 26, 2021 Category: OBGYN Tags: Geburtshilfe Frauenheilkd Source Type: research